Latest News

QS Pharma receives approval from European Medicines Agency for commercial manufacture

QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan Philadelphia, US, and Nottingham, UK, 27th June 2017: QS Pharma, the Contract Development and Manufacturing Organisation (CDMO), which was acquired by Quotient Clinical (“Quotient”) in February 2017, today announced it has received approval from the European […]

Read more..

Quotient Clinical appoints Azhar Kalim as Chief Commercial Officer

Appointment supports Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions Nottingham, UK, 30th May 2017: Quotient Clinical (“Quotient”), the drug development services provider, today announced the appointment of Azhar Kalim as Chief Commercial Officer (CCO). Azhar will lead the enhanced commercial team in a new role, with a focus […]

Read more..

Quotient Clinical announces second US acquisition: QS Pharma

Addition of contract development and manufacturing organisation increases scale of business and adds high potency molecule capability Follows recent acquisition of SeaView Research, the specialist clinical pharmacology business, to further extend US presence   Nottingham, UK, 14 February 2017 Quotient Clinical (“Quotient”), the early phase drug development services provider, today announces that it has acquired […]

Read more..
Back to top